Kehua to develop molecular diagnosis in collaboration with Seegene

  • 2018-10-19
On October 18th, Xi’an Tianlong Science and Technology Co., Ltd. (hereinafter referred to as “Tianlong”), an holding company of Shanghai Kehua Bio–engineering Co., Ltd. (hereinafter referred to as “Kehual”), signed a cooperation framework agreement with Seegene from South Korea. Both parties will develop, produce and market supporting molecular diagnostic reagents of PCR instruments produced by Tianlong by giving full play to their respective competitive edges in design, research, production and marketing. Both parties will establish and actively push forward a long term partnership in the hope of generating bigger commercial and value.

Main Content of the cooperation framework agreement

1. Seegene shall be responsible for the development of supporting molecular diagnostic reagents of PCR instruments produced by Tianlong.

2. Tianlong shall be responsible for the validation and verification of the products so that such products can obtain the regulatory approval from the China Food and Drug Administration for conducting clinical trials and all related activities. In addition, it shall also apply for permits and approval with other governments in order to market such products.

3. The two parties will further discuss specific cooperation matters on how Seegene can promote and market testing instruments of Tianlong in markets outside mainland China;

4. The agreement shall be valid for three years and can be extended by a written agreement signed by both parties.
Kehua is a high-tech company that integrates development, production and marketing of products, and comes with a complete industrial chain in vitro diagnostic products. Its business portfolio covers in-vitro diagnostic reagents and medical testing instruments. It possesses five product lines including biochemical diagnosis, enzyme-free diagnosis, light-free diagnosis, point-of-care testing (POCT), and molecular diagnosis independently.